1. Sanchez‐Paulete AR, Labiano S, Rodriguez‐Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, et al. Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapy. European Journal of Immunology 2016;46(3): 22-513.
2. Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports 2014;47(3):122.
3. Barsoumian HB, Yolcu ES, Shirwan H. 4-1BB signaling in conventional T cells drives IL-2 production that overcomes CD4+ CD25+ FoxP3+ T regulatory cell suppression. PloS One 2016;11(4):e0153088.
4. Kuang Y, Weng X, Liu X, Zhu H, Chen Z, Chen H. Effects of 4-1BB signaling on the biological function of murine dendritic cells. Oncology Letters 2012;3(2):81-477.
5. Bitra A, Doukov T, Croft M, Zajonc DM. Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier. Journal of Biological Chemistry 2018:jbc. RA118. 003176.
6. Sturgill ER. TNFR Agonists: A Review of Current Biologics Targeting OX40, 4-1BB, CD27, and GITR. American Journal of Hematology/Oncology 2017;13(11).
7. Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cellular & Molecular Immunology 2011;8(4):1-28.
8. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, et al. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. Journal of Experimental Medicine 2013;210(4):743-55.
9. Vinay DS, Kwon BS. Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies. Expert Opinion on Therapeutic Targets 2016;20(3):361-73.
10. Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood 2017:blood-2017-06-741041.
11. Dharmadhikari B, Wu M, Abdullah NS, Rajendran S, Ishak ND, Nickles E, et al. CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology 2016;5(4):e1113367.
12. Mbanwi AN, Watts TH, editors. Costimulatory TNFR family members in control of viral infection: outstanding questions. Seminars in Immunology; 2014: Elsevier.
13. Bartkowiak T, Curran MA. 4-1BB agonists: multi-potent potentiators of tumor immunity. Frontiers in Oncology 2015;5:117.
14. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228(4705):1315-7.
15. Keller T, Kalt R, Raab I, Schachner H, Mayrhofer C, Kerjaschki D, et al. Selection of scFv antibody fragments binding to human blood versus lymphatic endothelial surface antigens by direct cell phage display. PloS One 2015;10(5):e0127169.
16. Roncolato EC, Campos LB, Pessenda G, e Silva LC, Furtado GP, Barbosa JE. Phage display as a novel promising antivenom therapy: a review. Toxicon 2015;93:79-84.
17. Ma H, O’Kennedy R. Recombinant antibody fragment production. Methods 2017;116:23-33.
18. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. scFv antibody: principles and clinical application. Clinical and Developmental Immunology 2012;2012.
19. Qamsari ES, Sharifzadeh Z, Bagheri S, Riazi-Rad F, Younesi V, Abolhassani M, et al. Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies. Journal of Immunotoxicology 2017;14(1):23-30.
20. J.Abdolalizadeh JMz, M. Nouri. Isolation of Anti-tumor Necrosis Factor-Alpha(TNF-α) scFvs Antibody from phage antibody library. Journal of Babol University of Medical Sciences 2013;15(3):79-87.
21. Safarpour H, Shahmirzaie M, Rezaee E, Barati M, Safarnejad MR, Shirazi FH. Isolation and characterization of novel phage displayed scFv fragment for human Tumor necrosis factor alpha and molecular docking analysis of their interactions. Iranian journal of pharmaceutical research: Iranian Journal of Pharmaceutical Research 2018;17(2):743.
)